Can you discuss the recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the EULAR guidelines for RA? Where do IL-6 inhibitors fall into the treatment pathways?

Roy Fleischmann, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
Co-Director, Division of Rheumatology
Texas Health Presbyterian Medical Center and Co-Medical Director
Metroplex Clinical Research Center